AR086250A1 - Polipeptido de fusion presentador de una secuencia de aminoacidos y utilizacion del mismo - Google Patents

Polipeptido de fusion presentador de una secuencia de aminoacidos y utilizacion del mismo

Info

Publication number
AR086250A1
AR086250A1 ARP120101552A ARP120101552A AR086250A1 AR 086250 A1 AR086250 A1 AR 086250A1 AR P120101552 A ARP120101552 A AR P120101552A AR P120101552 A ARP120101552 A AR P120101552A AR 086250 A1 AR086250 A1 AR 086250A1
Authority
AR
Argentina
Prior art keywords
polypeptide
amino acid
fusion
derived
polipeptide
Prior art date
Application number
ARP120101552A
Other languages
English (en)
Inventor
Michael Gerg
Michael Schraeml
Vallribera David Casagolda
Hartmut Duefel
Herbert Andres
Christian Scholz
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR086250A1 publication Critical patent/AR086250A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y502/00—Cis-trans-isomerases (5.2)
    • C12Y502/01—Cis-trans-Isomerases (5.2.1)
    • C12Y502/01008—Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/99—Isomerases (5.)

Abstract

En la presente memoria se da a conocer un polipéptido de fusión según la fórmula (1):NH2-S2-X1-S1-COOH (1) en la que: X1 comprende una secuencia de aminoácidos aleatoria o una secuencia de aminoácidos derivada de un primer polipéptido, que corresponde a un epítopo oculto; S2 y S1 son secuencias de aminoácidos no solapantes derivadas de un segundo polipéptido, tal como SlyD procedente de una bacteria termófila o una arqueobacteria termófila y “-” se refiere a un enlace peptídico, en el que el segundo polipéptido es un polipéptido con actividad de peptidil-prolil cis/trans-isomerasa (actividad de PPIasa) o se deriva de la familia de dominios de pliegue de proteína cis-trans propil isomerasa (FKBP) en el que X1 se inserta en lugar del dominio de inserción en solapa del segundo polipéptido. La utilización de dicho polipéptido de fusión permite la inducción de una respuesta inmunológica contra X1 en un animal experimental. También se proveen métodos para producir un anticuerpo.
ARP120101552A 2011-05-05 2012-05-03 Polipeptido de fusion presentador de una secuencia de aminoacidos y utilizacion del mismo AR086250A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11164957 2011-05-05
EP12155742 2012-02-16

Publications (1)

Publication Number Publication Date
AR086250A1 true AR086250A1 (es) 2013-11-27

Family

ID=46022284

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120101552A AR086250A1 (es) 2011-05-05 2012-05-03 Polipeptido de fusion presentador de una secuencia de aminoacidos y utilizacion del mismo

Country Status (17)

Country Link
US (5) US9266962B2 (es)
EP (2) EP2705053B1 (es)
JP (3) JP6165713B2 (es)
KR (1) KR101632479B1 (es)
CN (2) CN103649119B (es)
AR (1) AR086250A1 (es)
AU (1) AU2012251584B2 (es)
BR (1) BR112013028134A2 (es)
CA (2) CA2831162C (es)
ES (1) ES2637667T3 (es)
IL (1) IL228983A0 (es)
MX (1) MX340329B (es)
MY (1) MY166542A (es)
RU (1) RU2630660C2 (es)
SG (1) SG194707A1 (es)
WO (2) WO2012150321A1 (es)
ZA (1) ZA201308251B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086250A1 (es) * 2011-05-05 2013-11-27 Hoffmann La Roche Polipeptido de fusion presentador de una secuencia de aminoacidos y utilizacion del mismo
WO2014071978A1 (en) * 2012-11-08 2014-05-15 Roche Diagnostics Gmbh Nucleic acids encoding chimeric polypeptides for library screening
US9429584B2 (en) * 2013-02-28 2016-08-30 National Cancer Center Antibody against insoluble fibrin
WO2014138733A2 (en) * 2013-03-08 2014-09-12 Dessain Scott K Compositions and methods for making human antibodies
EP3049437A1 (en) 2013-09-27 2016-08-03 F. Hoffmann-La Roche AG Thermus thermophilus slyd fkbp domain specific antibodies
MX2016014726A (es) * 2014-05-14 2017-03-23 Hoffmann La Roche Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.
BR112016025056A2 (pt) * 2014-05-14 2018-02-20 F. Hoffmann-La Roche Ag uso de pelo menos um polipeptídeo, anticorpo biespecífico, anticorpo biespecífico isolado, anticorpo her3/her2 biespecífico, célula hospedeira, método de produção do anticorpo biespecífico her3/her2, imunoconjugado e formulação farmacêutica
SG11201704362VA (en) 2014-12-01 2017-06-29 Pfenex Inc Fusion partners for peptide production
KR20170095364A (ko) * 2014-12-18 2017-08-22 비오메리으 합성 이중-에피토프 화합물
EP3233884B1 (en) 2014-12-19 2021-03-31 F. Hoffmann-La Roche AG Microbial transglutaminases, substrates therefor and methods for the use thereof
WO2016200219A1 (en) 2015-06-11 2016-12-15 Genexine, Inc. Modified interleukin-7 protein and uses thereof
CN106554420A (zh) * 2015-09-30 2017-04-05 上海众合医药科技股份有限公司 Pcsk9抗体、其抗原结合片段及其医药用途
KR102386735B1 (ko) 2015-11-06 2022-04-14 주식회사 제넥신 변형된 인터루킨-7 융합 단백질의 제형
US11708399B2 (en) 2015-12-04 2023-07-25 Genexine, Inc. Pharmaceutical composition comprising immunoglobulin Fc-fused interleukin-7 fusion protein for preventing or treating human papillomavirus-caused diseases
US11357827B2 (en) 2015-12-04 2022-06-14 Genexine, Inc. Method for preventing or treating influenza virus infection using pharmaceutical composition comprising immunoglobulin Fc-fused interleukin-7 fusion protein
EP3390424B1 (en) * 2015-12-15 2021-09-01 Roche Diagnostics GmbH Fkbp domain with transglutaminase recognition site
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
EP3760641A4 (en) * 2018-02-27 2021-11-24 Eisai R&D Management Co., Ltd. MONOCLONAL ANTIBODIES AGAINST APOA4, IMMUNOASSAY AND KIT FOR MEASUREMENT
JP2022550069A (ja) * 2019-09-26 2022-11-30 エフ．ホフマン－ラ ロシュ アーゲー 抗ｃｓｆ－１ｒ抗体
CN117529662A (zh) 2021-06-17 2024-02-06 豪夫迈·罗氏有限公司 热稳定的亲和多肽
WO2023012321A1 (en) * 2021-08-06 2023-02-09 Roche Diagnostics Gmbh Chimeric igg-fc-binding ligand polypeptide and uses thereof for igg affinity purification
WO2023021055A1 (en) 2021-08-19 2023-02-23 F. Hoffmann-La Roche Ag Multivalent anti-variant fc-region antibodies and methods of use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1232188A (en) 1987-05-29 1988-12-01 Mallinckrodt, Inc. Novel pair of monoclonal antibodies to insulin-like growth factor i permits immunometric assay for igf-i
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5614547A (en) * 1995-06-07 1997-03-25 Guilford Pharmaceuticals Inc. Small molecule inhibitors of rotamase enzyme
US7276355B2 (en) 2000-12-26 2007-10-02 Sekisui Chemical Co., Ltd. Process for production of a recombinant protein and a fusion protein
EP2267452B8 (en) * 2001-06-22 2012-11-14 Roche Diagnostics GmbH A soluble complex comprising a retroviral surface glycoprotein
JP4168028B2 (ja) * 2002-06-25 2008-10-22 積水化学工業株式会社 発現ベクター、宿主、融合タンパク質、融合タンパク質の製造方法及びタンパク質の製造方法
ATE374784T1 (de) * 2002-12-20 2007-10-15 Hoffmann La Roche Lösliche komplexe von zielproteinen und peptidyl- prolyl-isomerase-chaperonen sowie deren herstellung und verwendung
JPWO2004092221A1 (ja) * 2003-04-18 2006-07-06 積水化学工業株式会社 免疫原及び免疫用組成物、並びにそれらを使用する抗体の製造方法
US7732564B2 (en) * 2005-04-28 2010-06-08 London Health Sciences Centre Research Inc. Serum tumor marker in rodent prostate cancer models
EP1888034A2 (en) * 2005-05-26 2008-02-20 Yissum Research Development Company, of The Hebrew University of Jerusalem Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
US7604935B2 (en) * 2005-10-26 2009-10-20 Roche Diagnostics Operations, Inc. Soluble rubella E1 envelope protein variants
EP1780282B1 (en) 2005-10-26 2010-12-08 Roche Diagnostics GmbH Recombinant expression of Rubella E1 envelope protein variants as chaperone fusion-proteins, and their use in the detection of anti-Rubella antibodies
ATE527345T1 (de) * 2006-01-03 2011-10-15 Hoffmann La Roche Chimäres fusionsprotein mit überlegenen chaperon- und faltungsaktivitäten
KR20090029184A (ko) * 2006-04-07 2009-03-20 더 가브먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 항체 조성물 및 신생물성 질병의 치료 방법
WO2010052344A2 (en) * 2008-11-10 2010-05-14 Novartis Ag Antibodies to modified human igf-1/e peptides
AR086250A1 (es) * 2011-05-05 2013-11-27 Hoffmann La Roche Polipeptido de fusion presentador de una secuencia de aminoacidos y utilizacion del mismo
JP6488854B2 (ja) * 2015-04-22 2019-03-27 住友電気工業株式会社 半導体積層体および受光素子

Also Published As

Publication number Publication date
MX340329B (es) 2016-07-06
US20160137728A1 (en) 2016-05-19
ZA201308251B (en) 2014-08-27
US20160138004A1 (en) 2016-05-19
CA2834456A1 (en) 2012-11-08
SG194707A1 (en) 2013-12-30
WO2012150321A1 (en) 2012-11-08
CA2831162A1 (en) 2012-11-08
EP2705053B1 (en) 2017-06-14
EP2705053A1 (en) 2014-03-12
WO2012150320A1 (en) 2012-11-08
AU2012251584A1 (en) 2013-11-07
CN103649119A (zh) 2014-03-19
RU2013152691A (ru) 2015-06-10
CN103649119B (zh) 2016-06-08
US20190367601A1 (en) 2019-12-05
JP5877893B2 (ja) 2016-03-08
ES2637667T3 (es) 2017-10-16
MY166542A (en) 2018-07-16
AU2012251584B2 (en) 2016-07-28
IL228983A0 (en) 2013-12-31
CA2831162C (en) 2019-05-28
JP2014515761A (ja) 2014-07-03
US10301383B2 (en) 2019-05-28
US9938340B2 (en) 2018-04-10
EP2705147A1 (en) 2014-03-12
US20140120561A1 (en) 2014-05-01
NZ616871A (en) 2015-12-24
US20140178393A1 (en) 2014-06-26
CN103620031B (zh) 2016-11-23
MX2013012688A (es) 2013-12-02
CN103620031A (zh) 2014-03-05
US9266962B2 (en) 2016-02-23
JP6165713B2 (ja) 2017-07-19
US9273144B2 (en) 2016-03-01
KR101632479B1 (ko) 2016-06-21
JP2014520073A (ja) 2014-08-21
US10647765B2 (en) 2020-05-12
JP2017048209A (ja) 2017-03-09
KR20140004802A (ko) 2014-01-13
EP2705147B1 (en) 2019-08-07
BR112013028134A2 (pt) 2016-11-29
RU2630660C2 (ru) 2017-09-11

Similar Documents

Publication Publication Date Title
AR086250A1 (es) Polipeptido de fusion presentador de una secuencia de aminoacidos y utilizacion del mismo
NZ599259A (en) Mycobacterial vaccines
ES2564281T3 (es) Formulación de anticuerpos Abeta
MX2013013111A (es) Composicion inmunogenica que presenta antigeno multiple, y metodos y usos de la misma.
AR076107A1 (es) Vacunas anti-virales dirigidas contra celulas presentadoras de antigenos
WO2010104747A3 (en) Antigen presenting cell targeted vaccines
AR098875A1 (es) Medios para cultivo celular
PE20141172A1 (es) Composiciones de nucleasa terapeuticas y metodos
NZ597692A (en) Anti-IGF antibodies
PE20142115A1 (es) Composiciones de neisseria meningitidis y metodos de las mismas
CN110279853A (zh) 包含聚合载体货物复合物和至少一种蛋白或肽抗原的药物组合物
BRPI0721003B8 (pt) composições e uso
BR112018075688A2 (pt) anticorpos anti-c5 e métodos de uso
PE20121360A1 (es) Anticuerpos neutralizadores contra el receptor de prolactina
WO2012046061A3 (en) Clostridium difficile antigens
WO2008002663A3 (en) Immunogenic protein constructs
NZ594029A (en) Cna_b domain antigens in vaccines against gram positive bacteria
EA201490945A1 (ru) Набор, содержащий заменитель сыворотки и лабильные факторы
WO2012047679A3 (en) Consensus antigen constructs and vaccines made there form, and methods of using same to treat malaria
BR112014032544A2 (pt) método para produzir iduronato-2-sulfatase recombinante
GB201013215D0 (en) Expression of antibody or a fragment thereof in lactobacillus
BR112014003841A2 (pt) estratégia de múltiplas cópias para produção em alto título e alta pureza de proteínas de múltiplas subunidades tal como anticorpos em micróbios transformados tal como pichia pastoris
RU2014131056A (ru) Электрический вакуумный пылесос
WO2009143413A8 (en) Synergistic immunogenic fusion protein-polysaccharide conjugate
AR092630A1 (es) Metodos y composiciones para prevenir la incorporacion erronea de norleucina en proteinas

Legal Events

Date Code Title Description
FC Refusal